Loading...

A novel HSP90 inhibitor delays castrate resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis

PURPOSE: Prostate cancer responds initially to anti-androgen therapies, however, progression to castration resistant disease frequently occurs. Therefore there is an urgent need for novel therapeutic agents that can prevent the emergence of castration resistant prostate cancer (CRPC). Hsp90 is a mol...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Lamoureux, Francois, Thomas, Christian, Yin, Min-Jean, Kuruma, Hidetoshi, Fazli, Ladan, Gleave, Martin E, Zoubeidi, Amina
Format: Artigo
Sprog:Inglês
Udgivet: 2011
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4437585/
https://ncbi.nlm.nih.gov/pubmed/21349995
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-3077
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!